This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Friedreich ataxia (early-onset cerebellar ataxia)Friedreich Ataxia (Early-onset Cerebellar Ataxia)

Contents and key points
ItemDetails
A. Classification codesICD-10: G11.1 | Special Copayment Reduction: V123
B. SynonymsFriedreich ataxia, early-onset cerebellar ataxia
C. Adult onsetLikelihood of first onset in adulthood low — typically onset before age 25 (median 10–15 years), with some later-onset forms after age 25
1. HistoryFirst described by Nikolaus Friedreich in 1863; GAA repeat expansion in the FXN gene identified in 1996
2. CausesGAA repeat expansion (>66 repeats) in intron 1 of the FXN gene, frataxin protein deficiency, mitochondrial iron overload
3. GeneticsAutosomal recessive; about 96% homozygous GAA expansion, 4% compound heterozygous (expansion on one allele + point mutation on the other)
4. General epidemiologyThe most common inherited ataxia in people of European descent; prevalence about 1–2/50,000; carrier frequency 1/60–100
5. PathophysiologyFrataxin deficiency → mitochondrial iron accumulation → oxidative stress → impaired energy production → selective neuronal and cardiac damage
6. SymptomsMultisystem involvement, including gait ataxia, sensory impairment, cardiomyopathy, scoliosis, foot deformity, and diabetes
7. SignsLoss of tendon reflexes, sensory impairment, positive Babinski sign, gait ataxia, eye movement abnormalities
8. ScreeningFXN GAA repeat analysis in children and adolescents with early-onset ataxia; ECG and echocardiography screening
9. DiagnosisMolecular genetic testing of FXN GAA repeat number, nerve conduction studies (absent sensory nerve action potentials), brain and spinal cord MRI
10. TreatmentFDA approval of omaveloxolone, rehabilitation, cardiac management, diabetes control, gene therapy clinical trials
11. PrognosisMost become wheelchair-dependent in their 20s–30s; shortened mean life expectancy (main causes of death: heart failure, arrhythmia)
12. PreventionGenetic counseling, carrier testing, prenatal and preimplantation genetic diagnosis, early detection and prevention of cardiac complications
13. ReferencesCampuzano V et al. Science 1996 and 9 other papers

1. History

Friedreich ataxia is a disease first systematically described in 1863 by the German neurologist Nikolaus Friedreich in a series of papers. He reported cases of 5 patients from families showing progressive gait ataxia, sensory impairment, scoliosis, and foot deformity, and showed clinically and pathologically that the disease results from degeneration of the posterior and lateral tracts of the spinal cord. It subsequently became known as "Friedreich's spinal ataxia."

In the early 20th century, the clinical criteria were refined, and in 1984 Geoffroy et al. proposed standard diagnostic criteria including "gait ataxia with loss of tendon reflexes, onset before age 25, dysarthria, ECG abnormalities, and foot deformity or scoliosis." These criteria were later refined as the "Harding criteria" and became the basis of clinical diagnosis before the molecular genetic era.

In 1988, family linkage analysis confirmed that the disease gene is located on the long arm of chromosome 9 (9q13), and in 1996 Campuzano et al. established that the cause is a GAA trinucleotide repeat expansion in intron 1 of the FXN (frataxin) gene. This was one of the first discoveries of a trinucleotide repeat expansion occurring in an untranslated intron rather than a coding region and causing suppression of gene expression. In 2023, omaveloxolone was approved by the US FDA as the first approved treatment for Friedreich ataxia, opening a new era of treatment.

2. Causes

The cause of Friedreich ataxia is a GAA trinucleotide repeat expansion in intron 1 of the FXN (frataxin) gene, located on the long arm of chromosome 9 (9q21.11). In normal individuals, the GAA repeat number is about 5–33, and pathological expanded alleles carry 66 or more GAA repeats (usually 200–900). The GAA repeat expansion forms unusual double-stranded DNA structures (R-loop, sticky DNA) that epigenetically suppress transcription of the FXN gene.

As a result, expression of frataxin, a mitochondrial iron-sulfur cluster protein, is reduced to 5–30% of normal. Frataxin regulates iron-sulfur cluster synthesis in mitochondria and is essential for normal iron metabolism and maintenance of mitochondrial function. In frataxin deficiency, free iron accumulates in mitochondria, and reactive oxygen species (ROS) are overproduced through the Fenton reaction, increasing oxidative stress.

In about 4% of patients, the disease occurs in a compound heterozygous form, with a GAA expansion on one allele and an FXN point mutation or deletion on the other. In this case, the phenotype may differ somewhat from the typical clinical picture. The length of the GAA repeat shows an inverse correlation with age of onset and some aspects of clinical severity, and the GAA number of the longer allele (shorter allele) is more strongly associated with phenotype.

3. Genetics

Friedreich ataxia follows an autosomal recessive inheritance pattern. The disease develops only when both alleles carry pathogenic mutations, and carriers are asymptomatic. In populations of European descent, the carrier frequency is relatively high at about 1/60–1/100. About 96% of patients are homozygotes with GAA repeat expansions on both FXN alleles.

The GAA repeat number may show instability on intergenerational transmission, with a tendency for the repeat number to decrease on maternal transmission and increase on paternal transmission. This is why anticipation is not typical compared with other trinucleotide repeat diseases such as Huntington disease. Intermediate alleles (34–65 repeats) between the normal range (5–33) and the pathological range (66 or more) may act as precursors of pathological expansion.

In the rarely found compound heterozygous patients (4%), one allele carries a point mutation (missense, nonsense, splice site) or small deletion. In this case, FXN protein is not produced at all, or a small amount of nonfunctional protein is produced. In the genotype-phenotype correlation, the repeat number of the shorter GAA repeat allele correlates with age of onset and some clinical features (cardiac involvement, presence of reflex loss, etc.).

4. General epidemiology

Friedreich ataxia is the most common inherited ataxia in populations of European and North African descent. Its prevalence is estimated at about 1–2/50,000, with regional variation within Europe. Prevalence in Asian and African populations is lower than in those of European descent, but sporadic cases are reported. It is rare in East Asia, including Korea, but domestic cases have been reported.

The median age of onset is 10–15 years, with onset usually between ages 5 and 25. "Late-onset FA (LOFA)" begins after age 25 and "very late-onset FA (VLOFA)" after age 40, and these are associated with relatively small GAA repeat numbers. The male-to-female ratio is equal. There are estimated to be about 15,000–20,000 patients worldwide. The high carrier frequency of about 1/60–1/100 in the general population of European descent is why this disease is relatively common even among rare ataxias.

In Korea, it is registered and managed under Special Copayment Reduction code V123, and although exact patient numbers vary with updates to official statistics, they are estimated at several dozen to several hundred. Diagnosis rates are improving along with better access to genetic testing.

5. Pathophysiology

The core of the pathogenesis of Friedreich ataxia is mitochondrial dysfunction due to frataxin deficiency. Frataxin is a protein located in the mitochondrial matrix that functions as a component of the iron-sulfur cluster (Fe-S cluster) synthesis complex (ISC assembly machinery). Iron-sulfur clusters are essential cofactors of mitochondrial electron transport chain complexes I, II, and III, aconitase, and others.

In frataxin deficiency, iron-sulfur cluster synthesis is reduced, and free iron (labile iron pool) accumulates in mitochondria. The accumulated iron overproduces reactive oxygen species through the Fenton reaction (Fe2+ + H2O2 → Fe3+ + OH• + OH-), which causes oxidative damage to lipids, proteins, and DNA. ATP production decreases because of reduced electron transport chain efficiency, making neurons and cardiomyocytes with high energy dependence selectively vulnerable.

Pathologically, loss of nerve fibers in the posterior columns, spinocerebellar tracts, and corticospinal tracts is prominent. Loss of large myelinated neurons in the dorsal root ganglia explains the sensory symptoms. Neuronal loss in the cerebellar dentate nucleus causes impaired motor control. Dilated and hypertrophic changes in myocardial fibers also occur progressively.

Transcriptional suppression of the FXN gene occurs epigenetically, as the expanded GAA repeat induces a heterochromatin structure. It is known that histone deacetylase (HDAC) inhibitors can experimentally increase FXN expression, and this is the rationale for HDAC inhibitor-based treatment strategies.

6. Symptoms

Friedreich ataxia is a multisystem disease in which neurological and non-neurological symptoms (cardiac, endocrine, musculoskeletal) occur in combination. The first symptom is usually gait ataxia, which starts in the lower limbs and gradually spreads to the upper limbs and trunk. Difficulty with balance, frequent falls, and unsteady gait begin in adolescence.

Among sensory symptoms, reduced vibration and position sense (proprioception) in the distal lower limbs are prominent, which is due to loss of dorsal root ganglion neurons. Pain and temperature sensation are relatively preserved. Dysarthria, as slow and irregular cerebellar speech, occurs in most patients. Intention tremor of the hands and difficulty with handwriting appear.

Cardiac complications occur in about 60–80%, with hypertrophic cardiomyopathy being the most common. Arrhythmias (such as atrial fibrillation) are also common and can progress to heart failure. Diabetes or impaired glucose tolerance occurs in about 30%. Scoliosis and foot deformity (pes cavus) are present in most. Fatigue, bladder dysfunction, and visual and hearing impairment are also reported. About 10–15 years after onset, most patients become unable to walk.

7. Signs

The most characteristic finding on neurological examination is loss of deep tendon reflexes. Knee and ankle reflexes are lost from early on, reflecting sensory neuropathy due to loss of dorsal root ganglion neurons. A positive Babinski sign appears, suggesting upper motor neuron involvement. The coexistence of tendon reflex loss and a positive Babinski sign is a highly characteristic combination of Friedreich ataxia.

On sensory testing, vibration and position sense in the distal lower limbs are markedly reduced or absent. The Romberg test is positive, and balance deteriorates markedly when visual compensation is removed. On gait testing, a wide-based unsteady gait is observed, and tandem walking is very difficult.

Scoliosis and foot deformity (pes cavus) are observed in most and suggest structural deformities of neuromuscular origin. Eye movement abnormalities include saccadic abnormalities and gaze-evoked nystagmus. Dysarthria appears as a slow, indistinct pronunciation pattern. Cardiac examination may reveal murmurs, arrhythmias, and cardiomegaly, and ECG and echocardiography are essential.

8. Screening

Screening for Friedreich ataxia is done in children and adolescents with early-onset progressive ataxia. Early suspicion is needed especially when onset is before age 25, tendon reflexes are absent, and there is a family history or parental consanguinity. Molecular genetic testing of FXN GAA repeat number is the most important screening and diagnostic tool.

Cardiac screening is mandatory in all diagnosed patients. Electrocardiography (ECG) and echocardiography are performed at initial diagnosis and regularly thereafter (every year or every 2 years) for early detection of hypertrophic cardiomyopathy and arrhythmias. Diabetes screening with blood glucose testing and glycated hemoglobin (HbA1c) is also performed regularly from the time of diagnosis.

Spinal radiographs assess the presence of scoliosis and the Cobb angle, and regular follow-up is needed to monitor scoliosis progression. Siblings in the family can be diagnosed early through genetic testing regardless of symptoms. Carrier testing is offered to family members for reproductive planning.

9. Diagnosis

Friedreich ataxia is confirmed by molecular genetic testing of FXN GAA repeat number. The GAA repeat number is quantified by PCR-based fragment length analysis or repeat-primed PCR, and a homozygous diagnosis is established when GAA expansions of 66 or more repeats are identified on both alleles. When there is an expansion on one allele and a point mutation is suspected on the other, FXN gene sequencing is added.

Nerve conduction studies support the diagnosis by demonstrating absent or markedly reduced sensory nerve action potentials (SNAPs). This is an axonal sensory neuropathy pattern due to loss of dorsal root ganglion neurons. Motor nerve conduction is mostly normal or mildly reduced.

Brain and spinal cord MRI may show spinal cord atrophy (especially cervical) and signal abnormalities of the cerebellar dentate nucleus. Reduced cerebellar volume is more prominent in advanced disease. ECG shows left ventricular hypertrophy, T-wave inversion, ST changes, and so on, and echocardiography confirms findings of hypertrophic cardiomyopathy. Measurement of frataxin protein levels in blood (ELISA-based) is possible and is used as an adjunct to diagnosis.

10. Treatment

In 2023, omaveloxolone (Skyclarys) was approved by the US FDA as the first approved drug for Friedreich ataxia in patients aged 16 years or older. Omaveloxolone acts by activating the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway, strengthening antioxidant defense mechanisms and improving mitochondrial function. The phase 3 MOXIe trial demonstrated significant improvement in a measure of motor function (mFARS).

Other symptomatic treatments include rehabilitation (physical, occupational, and speech therapy), orthoses, and walking aids. Scoliosis is detected early, and physical therapy and, if necessary, surgical correction are considered. For cardiac management, ACE inhibitors and beta-blockers are used for heart failure, antiarrhythmics for arrhythmias, and heart transplantation is also considered for severe heart failure. Diabetes follows standard glycemic control protocols.

Investigational treatments include strategies aimed at increasing FXN gene expression. Antisense oligonucleotide (ASO)-based approaches, HDAC inhibitors (such as RG2833), FXN gene activation through epigenome editing, AAV-based gene therapy (FXN gene replacement), and frataxin protein stabilizers (e.g., frataxin fusion proteins) are in clinical trials or at the preclinical stage. Oligonucleotide-based agents such as DT-216 have recently attracted attention for increasing frataxin levels in preclinical studies.

11. Prognosis

Friedreich ataxia is a progressive disease in which neurological and cardiac function gradually decline. On average 10–15 years after onset, most patients become unable to walk and need a wheelchair. Given a mean age of onset of 10–15 years, loss of mobility occurs in most in their 20s–30s. Life expectancy is shortened compared with healthy individuals, and the mean age at death is about 40–50s.

Cardiac complications due to heart failure and arrhythmias account for about 60% of the main causes of death, and aspiration pneumonia is the second major cause of death. A long GAA repeat number (earlier onset) and severe cardiac involvement are poor prognostic factors. The late-onset form (LOFA) progresses slowly with less severe cardiac involvement and has a relatively better prognosis.

With the approval of omaveloxolone, disease-modifying treatment is now possible, so improvement in prognosis is expected in the future. Prevention of complications through early diagnosis and multidisciplinary management has an important effect on prognosis. In particular, early detection and treatment of cardiac complications contribute directly to prolonged survival. If new treatment strategies such as gene therapy succeed, prognosis could improve greatly.

12. Prevention

Because Friedreich ataxia is an autosomal recessive genetic disease, when both parents are carriers, 25% of children may be affected. The key prevention strategy is to assess risk within the family through genetic counseling and to offer options of prenatal diagnosis or preimplantation genetic testing (PGT-M) in future pregnancies.

Early genetic testing of siblings can identify carriers or those who will develop the disease before symptoms appear, in which case early surveillance for cardiac and metabolic complications can begin. Carrier testing is also considered, particularly for partners of patients with Friedreich ataxia, and used for family planning.

From the perspective of secondary prevention (prevention of complications), early detection and active treatment of cardiac complications, early diagnosis of diabetes and glycemic control, and early detection of scoliosis and physical therapy are important. Regular exercise and rehabilitation help maintain function, and environmental modifications to prevent falls are also needed. Antioxidant supplements to reduce oxidative stress (vitamin E, coenzyme Q10, etc.) are used in some clinical settings, but evidence of their effectiveness is still limited.

13. References

  1. Campuzano V, Montermini L, Molto MD, et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423-1427. PMID:8596916
  2. Lynch DR, Farmer JM, Balcer LJ, Wilson RB. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol. 2002;59(5):743-747. PMID:12020258
  3. Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1-2):46-49. PMID:21621226
  4. Strawser C, Schadt K, Hauser L, et al. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother. 2017;17(9):895-907. PMID:28728544
  5. Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA. 1999;96(20):11492-11495. PMID:10500204
  6. Marmolino D. Friedreich's ataxia: past, present and future. Brain Res Rev. 2011;67(1-2):311-330. PMID:21550351
  7. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256 Suppl 1:3-8. PMID:19283344
  8. Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011;303(1-2):1-12. PMID:21367430
  9. Lynch DR, Chin MP, Delatycki MB, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study). Ann Neurol. 2021;89(2):212-225. PMID:33036083
  10. Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol. 2012;27(9):1133-1137. PMID:22752493